Shire has entered into an agreement with Shionogi & Co. Ltd. to co-develop and co-commercialize certain Attention Deficit Hyperactivity Disorder (ADHD) medicines in Japan.

Shionogi will pay a one-time fee and share costs with Shire in exchange for rights to jointly co-develop and co-commercialize the products upon approval for the Japanese market.

“We look forward to working with the Shionogi team on efforts to enhance awareness in Japan about the impact undiagnosed and untreated ADHD can have on our societies,” says Mike Yasick, senior vice president of Shire’s ADHD business.

Release Date: Nov. 18, 2011
Source: Shire